Insights on distinct pathways of thiazolidinediones (PPAR? ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells

International Journal of Cancer

Volumn 127, Issue 8, 2010, Pages 1769-1784

  Plissonnier, Marie Laure ^a   Fauconnet, Sylvie ^a,b   Bittard, Hugues ^b   Lascombe, Isabelle ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^b HÔPITAL SAINT JACQUES   (France)

Author keywords

apoptosis; bladder cancer cells; c FLIP; cell cycle arrest; PPAR?; surviving; thiazolidinediones; TRAIL

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLICE INHIBITORY PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; SURVIVIN; TROGLITAZONE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; 2,4 THIAZOLIDINEDIONE DERIVATIVE; BIRC5 PROTEIN, HUMAN; CFLAR PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UNDIFFERENTIATED CARCINOMA; UPREGULATION; UROTHELIUM; BLADDER TUMOR; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECT; DRUG RESISTANCE; FLOW CYTOMETRY; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

APOPTOSIS; BLOTTING, WESTERN; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL CYCLE; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PPAR GAMMA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; THIAZOLIDINEDIONES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTIONAL ACTIVATION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 77957013134     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25189     Document Type: Article

References (51)

1. Day C,. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-92.
2. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA,. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
3. Willson TM, Lehmann JM, Kliewer SA,. Discovery of ligands for the nuclear peroxisome proliferator-activated receptors. Ann N Y Acad Sci 1996; 804: 276-83.
4. Rumi MA, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y,. Can PPAR gamma ligands be used in cancer therapy? Curr Med Chem Anticancer Agents 2004; 4: 465-77.
5. Guan Y, Zhang Y, Davis L, Breyer MD,. Expression of peroxisome proliferator-activated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-F1022.
6. Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N, Hattori K, Reddy JK, Oyasu R,. Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells. Am J Pathol 2001; 159: 591-7.
7. Yoshimura R, Matsuyama M, Hase T, Tsuchida K, Kuratsukuri K, Kawahito Y, Sano H, Segawa Y, Nakatani T,. The effect of peroxisome proliferator-activated receptor-gamma ligand on urological cancer cells. Int J Mol Med 2003; 12: 861-5.
8. Chaffer CL, Thomas DM, Thompson EW, Williams ED,. PPARgamma-independent induction of growth arrest and apoptosis in prostate and bladder carcinoma. BMC Cancer 2006; 6: 53.
9. Wei S, Yang J, Lee SL, Kulp SK, Chen CS,. PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett 2009; 276: 119-24.
10. Huang Y, Sheikh MS,. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 2007; 224: 284-9.
11. Kruyt FA,. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25.
12. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-63.
13. Steele LP, Georgopoulos NT, Southgate J, Selby PJ, Trejdosiewicz LK,. Differential susceptibility to TRAIL of normal versus malignant human urothelial cells. Cell Death Differ 2006; 13: 1564-76.
14. Fauconnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W, Bittard H,. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem 2002; 277: 23534-43.
15. Boiteux G, Lascombe I, Roche E, Plissonnier ML, Clairotte A, Bittard H, Fauconnet S,. A-FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. Int J Cancer 2009; 124: 1820-8.
16. Scaffidi C, Schmitz I, Krammer PH, Peter ME,. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999; 274: 1541-8.
17. Jesenberger V, Jentsch S,. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 2002; 3: 112-21.
18. Campbell MJ, Carlberg C, Koeffler HP,. A role for the PPARgamma in cancer therapy. PPAR Res 2008; 2008: 314974.
19. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M,. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005; 90: 1332-9.
20. Aiello A, Pandini G, Frasca F, Conte E, Murabito A, Sacco A, Genua M, Vigneri R, Belfiore A,. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 2006; 147: 4463-75.
21. Lyles BE, Akinyeke TO, Moss PE, Stewart LV,. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways. Cell Cycle 2009; 8: 268-77.
22. Rageul J, Mottier S, Jarry A, Shah Y, Theoleyre S, Masson D, Gonzalez FJ, Laboisse CL, Denis MG,. KLF4-dependent, PPARgamma-induced expression of GPA33 in colon cancer cell lines. Int J Cancer 2009; 125: 2802-9.
23. Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S,. Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 2003; 63: 958-64.
24. Han S, Sidell N, Fisher PB, Roman J,. Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells. Clin Cancer Res 2004; 10: 1911-19.
25. Sherr CJ,. G1 phase progression: cycling on cue. Cell 1994; 79: 551-5.
26. Pei XH, Xiong Y,. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene 2005; 24: 2787-95.
27. Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM,. Inhibition of bladder tumor growth by 1,1-bis(3?-indolyl)-1-(p- substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 2006; 66: 412-18.
28. Waldman T, Kinzler KW, Vogelstein B,. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-90.
29. Chen F, Harrison LE,. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell Signal 2005; 17: 809-16.
30. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD,. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
31. Akasaki Y, Liu G, Matundan HH, Ng H, Yuan X, Zeng Z, Black KL, Yu JS,. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells. J Biol Chem 2006; 281: 6165-74.
32. Schultze K, Bock B, Eckert A, Oevermann L, Ramacher D, Wiestler O, Roth W,. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 2006; 11: 1503-12.
33. Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS,. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. Endocr Relat Cancer 2006; 13: 401-13.
34. Bogazzi F, Ultimieri F, Raggi F, Russo D, Vanacore R, Guida C, Viacava P, Cecchetti D, Acerbi G, Brogioni S, Cosci C, Gasperi M, et al. PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas. Eur J Endocrinol 2004; 150: 863-75.
35. Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, Izaki H, Fukumori T, Takahashi M, Nishitani M, Kanayama HO,. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci 2006; 97: 1093-8.
36. Kim YH, Jung EM, Lee TJ, Kim SH, Choi YH, Park JW, Park JW, Choi KS, Kwon TK,. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic Biol Med 2008; 44: 1055-68.
37. Jung TI, Baek WK, Suh SI, Jang BC, Song DK, Bae JH, Kwon KY, Bae JH, Cha SD, Bae I, Cho CH,. Down-regulation of peroxisome proliferator-activated receptor gamma in human cervical carcinoma. Gynecol Oncol 2005; 97: 365-73.
38. Kim KY, Kim SS, Cheon HG,. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem Pharmacol 2006; 72: 530-40.
39. Kim Y, Suh N, Sporn M, Reed JC,. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J Biol Chem 2002; 277: 22320-9.
40. Goda AE, Yoshida T, Horinaka M, Yasuda T, Shiraishi T, Wakada M, Sakai T,. Mechanisms of enhancement of TRAIL tumoricidal activity against human cancer cells of different origin by dipyridamole. Oncogene 2008; 27: 3435-45.
41. Lu M, Kwan T, Yu C, Chen F, Freedman B, Schafer JM, Lee EJ, Jameson JL, Jordan VC, Cryns VL,. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005; 280: 6742-51.
42. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, Altieri DC,. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
43. Zhonghong L, Lianjie L, Changqing Z, Ying H, Yu J, Yan L,. The influence of survivin shRNA on the cell cycle and the invasion of SW480 cells of colorectal carcinoma. J Exp Clin Cancer Res 2008; 27: 20.
44. Fulda S, Debatin KM,. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-46.
45. Kim DJ, Murray IA, Burns AM, Gonzalez FJ, Perdew GH, Peters JM,. Peroxisome proliferator-activated receptor-beta/delta inhibits epidermal cell proliferation by down-regulation of kinase activity. J Biol Chem 2005; 280: 9519-27.
46. Perez-Ortiz JM, Tranque P, Vaquero CF, Domingo B, Molina F, Calvo S, Jordan J, Cena V, Llopis J,. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004; 279: 8976-85.
47. Turturro F, Friday E, Fowler R, Surie D, Welbourne T,. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin Cancer Res 2004; 10: 7022-30.
48. Chintharlapalli S, Papineni S, Baek SJ, Liu S, Safe S,. 1,1-Bis(3?-indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1. Mol Pharmacol 2005; 68: 1782-92.
49. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, Griffith TS,. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res 2004; 64: 3386-90.
50. Simons MP, O'Donnell MA, Griffith TS,. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol Oncol 2008; 26: 341-5.
51. Morales A, Eidinger D, Bruce AW,. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 180-3.